Fasting Insulin After 40: The Marker That Moves Years Before Blood Sugar

Nobody books an annual physical hoping to talk about insulin. You go in, the standard panel comes back, the fasting glucose line reads 94 mg/dL, and the conversation moves on to blood pressure. Three years later the same line reads 101. Two years after that, 109, and there is suddenly a word on the chart that was not there before.

The uncomfortable part is that nothing started three years ago. Fasting insulin after 40 tends to drift upward long before glucose budges, because the two numbers are measuring different things. Glucose is the scoreboard. Insulin is the effort it took to keep the score where it is. A body working twice as hard to hold the same line looks completely healthy on a standard panel, right up until it does not.

This is one of the few places in midlife health where a single inexpensive blood test can give you a five to ten year head start. It rarely gets ordered.

Why Fasting Insulin After 40 Starts to Drift

Insulin resistance is not a switch that flips. It is a slow renegotiation. Muscle and liver cells become slightly less responsive to insulin's signal, so the pancreas compensates by releasing more of it. Blood sugar stays normal because the compensation works. Fasting insulin climbs because the compensation is expensive.

Several things conspire after 40 to accelerate this. Muscle mass declines by roughly 3 to 8 percent per decade after 30 and faster after 50, and skeletal muscle is where most insulin-stimulated glucose disposal happens. Visceral fat accumulates even in people whose weight on the scale has not changed. Sleep gets shorter and more fragmented. Physical activity quietly compresses into fewer, shorter bouts. None of these is dramatic on its own. Together they shift the baseline.

A 2026 review in Nutrients argued that the clinical framework around insulin resistance is overdue for revision, in part because the condition is routinely identified only after glycemic markers deteriorate, by which point the compensatory phase has already run for years [1]. The authors make the case for treating insulin resistance as a measurable state in its own right rather than a precursor that only matters once glucose confirms it.

Glucose Is the Scoreboard, Insulin Is the Effort

Here is the practical version of that distinction. Two people walk in with identical fasting glucose of 92 mg/dL. One has a fasting insulin of 4 µIU/mL. The other has 17. The first is holding that glucose easily. The second is holding it by running the pancreas hot, every hour of every day.

On a standard metabolic panel, those two people are indistinguishable. And the second one is the one whose trajectory has already changed.

Research is increasingly able to see this earlier. A 2026 study in the Journal of Clinical Endocrinology and Metabolism mapped compartment-specific metabolic responses to insulin and found that these signatures reflected adiposity-driven variation and carried predictive value for future type 2 diabetes, independent of glucose alone [2]. The direction of travel in the literature is consistent: the insulin side of the equation carries information the glucose side does not.

The Oxidative Stress Layer Underneath the Number

So what drives the cells to stop listening? Part of the answer is mitochondrial. Insulin-sensitive tissues depend on mitochondria to oxidize fuel efficiently. When mitochondrial fuel handling degrades, lipid intermediates accumulate inside muscle and liver cells and interfere directly with insulin signaling. The cell is not being stubborn. It is congested.

Mitochondrial function and oxidative stress are tightly coupled, and this is where aging physiology enters the picture. Mitochondria are the primary source of reactive oxygen species, and they are also the tissue most vulnerable to them. The body's main intracellular defense against that damage is glutathione, a small tripeptide made from glycine, cysteine, and glutamate, present in nearly every cell and consumed continuously.

As the authors of a landmark 2011 study in the American Journal of Clinical Nutrition put it:

"Aging is associated with oxidative stress, but underlying mechanisms remain poorly understood."

That paper went looking for the mechanism, and found something specific enough to act on.

What the Glutathione Research Actually Shows

Using stable-isotope tracing in older and younger adults, Sekhar and colleagues measured not just how much glutathione was present but how fast it was being made. Older participants had red blood cell glutathione concentrations roughly half those of the younger group, and markedly lower synthesis rates. Their red blood cell glycine and cysteine levels, the raw materials, were also substantially depleted [3].

The interesting half came next. After two weeks of supplying those two precursors, glutathione concentrations in the older group rose by about 95 percent and absolute synthesis rates by more than 200 percent, with measurable reductions in oxidative stress markers including F2-isoprostanes [3].

The implication matters for how you think about antioxidants generally. This was not a case of adding an external antioxidant and hoping it reached the right place. It was a production-line problem. The machinery was intact and the inputs had run short.

A 2026 Nutrients review of glutathione supplementation in type 2 diabetes and its complications reached a similar structural conclusion, describing glutathione deficiency as a consistent hallmark in the condition and noting that augmentation has been linked to improved insulin sensitivity and reduced oxidative damage, while being clear that the findings remain preliminary and heterogeneous [4]. That review also reported a favorable safety profile across populations, with gastrointestinal discomfort the most commonly noted side effect.

The GlyNAC Trials: Replacing What Is Missing

The follow-up work tested whether correcting glutathione synthesis changes anything functional, and the results are more interesting than most supplement literature.

In a pilot clinical trial published in Clinical and Translational Medicine, older adults supplemented with glycine and N-acetylcysteine for 24 weeks showed improvements across glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genomic damage, muscle strength, and cognition [5]. Many of those measures regressed after supplementation stopped, which is itself informative. It suggests the effect depends on ongoing availability rather than a permanent reset.

A separate pilot study in Antioxidants looked specifically at patients with type 2 diabetes and reported improvements in impaired mitochondrial fuel oxidation alongside lower insulin resistance [6]. That pairing is the mechanistic story in one sentence: fuel handling improves, and the insulin burden eases.

The strongest design in this line of work is a randomized clinical trial published in the Journals of Gerontology: Series A, in which GlyNAC supplementation in older adults improved glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, physical function, and several measured hallmarks of aging [7].

These are small trials from a concentrated research group, and that limitation is real. The sample sizes are in the dozens, not the thousands, and larger independent replication is still needed. But the consistency between the mechanism, the biomarkers, and the functional outcomes is unusual for this category.

How to Test and Read the Result

Fasting insulin is a cheap, widely available test that almost never appears on a routine panel unless you ask for it. Request it alongside your standard fasting glucose, after a genuine 8 to 12 hour fast, and ask for both numbers on the same draw.

With both values you can calculate HOMA-IR, a decades-old index of insulin resistance: fasting insulin in µIU/mL multiplied by fasting glucose in mg/dL, divided by 405. Interpretation ranges vary between labs and populations, and your clinician should be the one to read it in context, but the general pattern in the literature is that lower is better and that the trend over several draws tells you more than any single value.

Two things worth knowing before you test. Insulin assays are not well standardized between labs, so compare results from the same lab where possible. And a single reading can be thrown off by a short night of sleep, an unusually large meal the evening before, or an acute illness. Retest rather than react.

What Actually Moves the Number

Nothing in the glutathione literature displaces the fundamentals, and anyone selling that framing is overselling.

Resistance training is the single highest-leverage intervention, because it rebuilds the tissue that does most of the glucose disposal. Two sessions a week is enough to matter. Walking after meals blunts post-meal glucose and insulin excursions measurably. Protecting sleep duration improves insulin sensitivity within days. Reducing liquid sugar and refined starch lowers the demand side directly. Losing visceral fat specifically, as opposed to weight generally, improves the picture more than the scale suggests.

Those levers come first. The redox and mitochondrial research is best understood as addressing a different part of the same system: the cellular environment in which those levers operate. For adults in their 40s and 50s who are already doing the training and the sleep and still watching the number drift, that distinction is worth understanding. At RenuviaRX, glutathione is one of the therapies our physicians discuss in exactly that context, as cellular support alongside the work, never as a replacement for it.

The Head Start Is the Point

The reason fasting insulin is worth asking about is not that it predicts something terrible. For most people it predicts something slow, gradual, and genuinely modifiable. But you cannot modify what you never measured, and the compensatory years are the ones where intervention is easiest and cheapest.

Ask for the test at your next draw. Get a second reading six months later. If the trend is flat and low, you have bought yourself real peace of mind for the cost of one extra line on a lab slip. If it is climbing, you have found it during the window when climbing is still the easy problem.

If you want to understand how physician-supervised cellular support fits alongside the work you are already doing, our board-certified physicians can walk through your options and whether any of them make sense for you.

These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.

References

1. Rodzeń Ł, Rodzeń M, Dyńka D, Łojko D, Karakuła-Juchnowicz H, Kraszewski S, Fazio S, Unwin D, Bikman B. Insulin Resistance: Current State of Knowledge and Clinical Implications, Toward a Better Diagnostic Framework and the Question of Its Disease Status. Nutrients. 2026;18(16):2666. https://doi.org/10.3390/nu18162666

2. Sevilla-González M, Hanson PA, Islam J, Hsu S, Tsoukas MA, Marliss EB, Reiner AP, Gravel M, Kooperberg C, Clish CB, Manning AK, Sladek R, Meigs JB, Burgos SA. Compartment-specific Metabolic Alterations to Insulin Reflect Adiposity-driven Variation and Predict Type 2 Diabetes. The Journal of Clinical Endocrinology and Metabolism. 2026;111(3):820-831. https://doi.org/10.1210/clinem/dgaf454

3. Sekhar RV, Patel SG, Guthikonda AP, Reid M, Balasubramanyam A, Taffet GE, Jahoor F. Deficient synthesis of glutathione underlies oxidative stress in aging and can be corrected by dietary cysteine and glycine supplementation. The American Journal of Clinical Nutrition. 2011;94(3):847-853. https://doi.org/10.3945/ajcn.110.003483

4. Au S, Dawi J, Affa S, Misakyan Y, Gonzalez E, Chorbajian A, Hammi M, Dave P, Qumsieh K, Venketaraman V. Efficacy and Safety of Glutathione Supplementation in Type 2 Diabetes and Diabetes Complications. Nutrients. 2026;18(13):2132. https://doi.org/10.3390/nu18132132

5. Kumar P, Liu C, Hsu JW, Chacko S, Minard C, Jahoor F, Sekhar RV. Glycine and N-acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition: Results of a pilot clinical trial. Clinical and Translational Medicine. 2021;11(3):e372. https://doi.org/10.1002/ctm2.372

6. Sekhar RV. GlyNAC (Glycine and N-Acetylcysteine) Supplementation Improves Impaired Mitochondrial Fuel Oxidation and Lowers Insulin Resistance in Patients with Type 2 Diabetes: Results of a Pilot Study. Antioxidants. 2022;11(1):154. https://doi.org/10.3390/antiox11010154

7. Kumar P, Liu C, Suliburk J, Hsu JW, Muthupillai R, Jahoor F, Minard CG, Taffet GE, Sekhar RV. Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial. The Journals of Gerontology: Series A. 2023;78(1):75-89. https://doi.org/10.1093/gerona/glac135